Literature DB >> 8516218

AIDS-myelopathy. A neuropathological study.

M Bergmann1, F Gullotta, K Kuchelmeister, T Masini, G Angeli.   

Abstract

Vacuolar myelopathy belongs to the AIDS-associated diseases. It is characterized by vacuolation and infiltration of the long tracts of the spinal cord by macrophages. The clinical and morphological findings of 8 AIDS-patients with vacuolar myelopathy are reported here. The syndrome developed during the final stages of AIDS and was associated with HIV-encephalopathy in 5 cases. The vacuoles were mainly due to intramyelinic swelling and vacuolation. Vacuolated macrophages and axons contributed only to a minor degree. In one case only, HIV-antigens were detected immunohistochemically. The results are discussed in the light of modern pathogenetical concepts of HIV-related diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8516218      PMCID: PMC7130719          DOI: 10.1016/S0344-0338(11)80117-2

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  39 in total

1.  Morphology and distribution of HIV-1 gp41-positive microglia in subacute AIDS encephalitis. Pattern of involvement resembling a multisystem degeneration.

Authors:  K Kure; K M Weidenheim; W D Lyman; D W Dickson
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

2.  [Morphology of vacuolar changes in the spinal cord of AIDS patients (vacuolar myelopathy)].

Authors:  J Artigas; G Grosse; S Habedank; W Heise; F Niedobitek
Journal:  Pathologe       Date:  1990-09       Impact factor: 1.011

3.  [The morphology of HIV encephalopathy].

Authors:  F Gullotta; K Kuchelmeister; T Masini; P Ghidoni; E Cappricci
Journal:  Zentralbl Allg Pathol       Date:  1989

4.  Myelopathies and retroviral infections.

Authors:  R T Johnson; J C McArthur
Journal:  Ann Neurol       Date:  1987-02       Impact factor: 10.422

5.  The role of HTLV in HIV-1 neurologic disease.

Authors:  J R Berger; S Raffanti; A Svenningsson; M McCarthy; S Snodgrass; L Resnick
Journal:  Neurology       Date:  1991-02       Impact factor: 9.910

Review 6.  HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease.

Authors:  J E Merrill; I S Chen
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

7.  Human immunodeficiency virus type 1 expression in the central nervous system correlates directly with extent of disease.

Authors:  B Weiser; N Peress; D La Neve; D J Eilbott; R Seidman; H Burger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

8.  Spinal cord and peripheral nerve pathology in AIDS: the roles of cytomegalovirus and human immunodeficiency virus.

Authors:  M R Grafe; C A Wiley
Journal:  Ann Neurol       Date:  1989-06       Impact factor: 10.422

9.  Immunohistochemical localization of human immunodeficiency viral antigens in formalin-fixed spinal cords with AIDS myelopathy.

Authors:  R H Rhodes; J M Ward; R P Cowan; P T Moore
Journal:  Clin Neuropathol       Date:  1989 Jan-Feb       Impact factor: 1.368

10.  Multifocal multinucleated giant cell myelitis in an AIDS patient.

Authors:  C Geny; R Gherardi; P Boudes; F Lionnet; P Cesaro; F Gray
Journal:  Neuropathol Appl Neurobiol       Date:  1991-04       Impact factor: 8.090

View more
  3 in total

Review 1.  [Imaging of demyelinating and neoplastic diseases of the spinal cord].

Authors:  C Mueller-Mang
Journal:  Radiologe       Date:  2010-12       Impact factor: 0.635

2.  Diffusion tensor MR imaging (DTI) metrics in the cervical spinal cord in asymptomatic HIV-positive patients.

Authors:  Christina Mueller-Mang; Meng Law; Thomas Mang; Julia Fruehwald-Pallamar; Michael Weber; Majda M Thurnher
Journal:  Neuroradiology       Date:  2010-11-03       Impact factor: 2.804

3.  Microbial Neuraminidase Induces a Moderate and Transient Myelin Vacuolation Independent of Complement System Activation.

Authors:  Pablo Granados-Durán; María Dolores López-Ávalos; Manuel Cifuentes; Margarita Pérez-Martín; María Del Mar Fernández-Arjona; Timothy R Hughes; Krista Johnson; B Paul Morgan; Pedro Fernández-Llebrez; Jesús M Grondona
Journal:  Front Neurol       Date:  2017-03-07       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.